Navigation Links
ELPHA 4 Conti

ProductsELPHA 4 Conti
Company Danmeter
Item ELPHA 4 Conti
Features 
  • ELPHA 4 Conti features pre-installed programmes with parameters based on the most up-to-date knowledge of the pelvic floor muscles.
  • On the one hand, the various type of muscle fibre (fast or slow twitch) can be targeted specifically, and on the other, the programme can be adjusted to enhance in treatment for individual requirements.
  • As something unique ELPHA 4 Conti offers symptomatic management of acute, chronic and cyclic pain syndromes with a dedicated pain relief programme of the pelvic floor and other muscle related pain with the use of surface electrodes.
Description ELPHA 4 Conti is a battery operated dual-channel therapy system designed for use in the treatment of conditions described below. ELPHA 4 Conti also includes a programme for treating pelvic pain. In STRESS- and faecal incontinence ELPHA 4 Conti provokes a contraction of the pelvic floor, so that the user can feel which muscles need exercising. In URGE incontinence, ELPHA 4 Conti helps normalise the micturition reflex, controlling the bladder function. The treatment is carried out in conjunction with the use of intra-vaginal or intra-rectal electrodes and the system can be used both in a clinic and at home.
Info Danmeter
Customer Service: +45 63 11 29 30
Web site: http://www.danmeter.dk/

Related medicine products :

1. ELPHA / ELPHA DL
2. Continuum Knee System
3. Continuum Primary Knee System
4. CGMS System Gold Continuous Glucose Monitoring
5. Continuous Wave II Arthroscopy Pump
6. DNA Engine Opticon Continuous Fluorescence Detection System
7. DNA Engine Opticon 2 Continuous Fluorescence Detection System
8. USA Elite System™ Rotating Continuous Flow Resectoscopes
9. Conti4000
10. Pelvicol Acellular Collagen Matrix (Continence)
11. Continuous Flow Cystoscopes
TAG: ELPHA Conti
mobileMICROMEDEX™ gives physicians, pharmacists, and other healthcare professionals reliable clinical information to help support and confirm treatment decisions. Clinicians can trust the data i
Focuses primarily on the drugs used for treatment and symptom management for colorectal cancer.
Portable Drug Companion is a comprehensive, authoritative drug reference to chose from over 5,500 entries, with overdose management, Canadian drug names, OTC and herbal remedies. This "Mini-Suite" of
The mission of AHFS DI Essentials (American Hospital Formulary Service) is to provide an evidence-based foundation for safe and effective drug therapy.
Medicine Products:
(Date:12/3/2008)...EVERLY HILLS, Dec. 3 As the classi...thin." However, it seems American women would rat...poll commissioned by ZO Skin,Health and reveals t...re on a,facial care system that would make them l...ogram that would make them lose 10 pounds. , ...
(Date:12/3/2008)... MONICA, Calif., Dec. 3 ...d President-elect Obama to oppose the health insur...equiring every American to buy junk insurance poli...n would not limit what insurers can charge or redu...test growing component of health care spending. As...
(Date:12/3/2008)...USTA, Ga. - Methods used by the body to selectivel... transplants safer and more effective, according t... to do is make every tissue transplant much more l...of the Medical College of Georgia Immunotherapy Ce... in Molecular Immunogenetics. , He,s referencing...
(Date:12/3/2008)...INGTON -- The U.S. Environmental Protection Agency... estimate the potential adverse effects posed by h... to protect public health -- is bogged down by unp...ol it is often hindered by a disconnect between av...of officials, says a new report from the National ...
Breaking Medicine News(10 mins):Health News:What Will Women Give Up for Skin Health? 2Health News:Consumer Watchdog Urges President-elect Obama to Continue to Oppose Mandatory Purchase of Junk Health Insurance 2Health News:Consumer Watchdog Urges President-elect Obama to Continue to Oppose Mandatory Purchase of Junk Health Insurance 3Health News:New approaches to protecting transplanted organs make first steps toward patients 2Health News:New approaches to protecting transplanted organs make first steps toward patients 3Health News:EPA's risk assessment process bogged down by unprecedented challenges; 2Health News:EPA's risk assessment process bogged down by unprecedented challenges; 3Health News:EPA's risk assessment process bogged down by unprecedented challenges; 4
... the combination of chemotherapy with a new medica...ents.// In the study of close to 1,000 patients, ... in patients who received chemotherapy and the ora... study show 65 patients who received the combined ...
...ause of blindness for blacks and whites is not the... the leading cause of blindness for whites, while ...lindness for blacks. More than 50 percent of the w...ion because of macular degeneration. In contrast, ...
...ns undergo balloon angioplasty to clear blocked ar... again.// Now, a cancer drug may change the outcom...knowing he's doing everything he can to avoid a se...years ago, he had a quintuple bypass operation. . ...
...t study researchers offer new insights about stret...ng before exercising.// Specialists say stretching...nt research shows static stretching makes muscles ...ease the risk of injury. They say some likely caus...
Other Medicine News:
(Date:12/1/2008)...d With ENB-0040 at Children,s Hospital, Health Sci... 1 Enobia Pharma, an emerging Cana...herapeutics for serious bone disorders, today anno...l program for hypophosphatasia was dosed. Enobia i...ith ENB-0040 for the treatment of this rare and of...
(Date:12/1/2008)...ire-FirstCall/ -- Genaera Corporation (Nasdaq: ... begun in study MSI-1436C-102 (Study 102), the mul...ne (MSI-1436) in overweight and obese type 2 diabe...tment of type 2 diabetes and obesity which works c...leptin pathways through the highly selective inhib...
(Date:12/1/2008)... -- GeoVax Labs, Inc.,(OTC Bulletin Board: GOVX),...,human vaccines for diseases caused by HIV-1 (Hum...gents, announced today that the launch of its Phas...ve sites across North and South America.,These tr...nal Institutes of,Health (NIH), and the HIV Vacci...
(Date:11/30/2008).../ -- Abnormalities in auditory and language proces...trum disorder by using magnetoencephalography (MEG...ual meeting of the Radiological Society of North A...d the tiny magnetic fields associated with electri...vice chair of research in the Department of Radiol...
Breaking Medicine Technology:Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Brain Waves Show Sound Processing Abnormalities in Autistic Children 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 3SemBioSys eligible to proceed with Phase I II plant produced insulin trial after submission of IND 7709 1SemBioSys eligible to proceed with Phase I II plant produced insulin trial after submission of IND 7709 2SemBioSys eligible to proceed with Phase I II plant produced insulin trial after submission of IND 7709 3Intact Medical Corporations Intact 28R 29 Excise XL Receives 510 28K 29 Marketing Clearance from the FDA 7708 1Intact Medical Corporations Intact 28R 29 Excise XL Receives 510 28K 29 Marketing Clearance from the FDA 7708 2BioCryst to Present at UBS 2008 Global Life Sciences Conference 7703 1BioCryst to Present at UBS 2008 Global Life Sciences Conference 7703 2BioCryst to Present at UBS 2008 Global Life Sciences Conference 7703 3Althea Technologies Secures 2412 M Credit Line to Continue Facility Growth and Expansion 7701 1Althea Technologies Secures 2412 M Credit Line to Continue Facility Growth and Expansion 7701 2
...E, Md., April 18, 2007--Due to water damage caused... to change the,location for the upcoming Antiviral...7 to discuss new drug application for,maraviroc 30...ld at,the FDA, Center for Drug Evaluation and Rese...0 Fishers Lane, in Rockville, MD, the,meeting has ...
...la., April 16, 2007 /PRNewswire/ -- Sirion Therape...al company, announced,today that it has received o...nistration (FDA) for its anti-viral therapy,ganci...tis. The,product is currently marketed by Laborato...(R). Sirion licensed the rights to,Virgan(R) for t...
Other Medicine Technology:FDA Announces Change of Location Notice for Upcoming Advisory,Committee Meeting 2Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic,Drug to Treat Viral Eye Infection 2